trending Market Intelligence /marketintelligence/en/news-insights/trending/1aFmhUIGNUZkNI5FA26e8A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Alimera Sciences names CEO, CFO under succession plan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Alimera Sciences names CEO, CFO under succession plan

Alimera Sciences Inc. promoted Richard Eiswirth Jr., who is also a president of the company, from CFO to CEO and named him to the board.

The executive change was made following the approval of a succession plan by Alimera's board that is intended to be effective Jan. 2.

Under the succession plan, C. Daniel Myers, co-founder of the company, retired as CEO and became a consultant to Alimera and nonexecutive board chairman.

Moreover, J. Philip Jones, the company's former vice president of finance, was appointed as CFO.

Philip Ashman, who was previously Alimera's senior vice president managing director Europe, was named as COO and senior vice president commercial operations Europe.

Alpharetta, Ga.-based Alimera Sciences is a pharmaceutical company, which engages in the research, development and commercialization of prescription ophthalmic, or eye-related, pharmaceuticals.